Biomarkers Before and After Nephrectomy of Locally Advanced or Metastatic Renal Cell Carcinoma Treated With Everolimus
Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
Disease and Stage: Metastatic and locally advanced clear cell renal carcinoma
An open-label, exploratory, single-arm, multicenter trial.
Everolimus will be administered orally, once daily, for 6 weeks followed by a 1-week rest
period prior to nephrectomy.
Two to four weeks after surgery, everolimus will be reintroduced only for metastatic patients
until disease progression, unacceptable toxicity, withdrawal of patient consent, or other
stopping rules are met.